RT Journal Article
SR Electronic
T1 Development of a potent Zika virus vaccine using self-amplifying messenger RNA
JF Science Advances
JO Sci Adv
FD American Association for the Advancement of Science
SP eaba5068
DO 10.1126/sciadv.aba5068
VO 6
IS 32
A1 Luisi, Kate
A1 Morabito, Kaitlyn M.
A1 Burgomaster, Katherine E.
A1 Sharma, Mayuri
A1 Kong, Wing-Pui
A1 Foreman, Bryant M.
A1 Patel, Sonal
A1 Fisher, Brian
A1 Aleshnick, Maya A.
A1 Laliberte, Jason
A1 Wallace, Madison
A1 Ruckwardt, Tracy J.
A1 Gordon, David N.
A1 Linton, Christine
A1 Ruggiero, Nicole
A1 Cohen, Jessica L.
A1 Johnson, Russell
A1 Aggarwal, Kunal
A1 Ko, Sung-Youl
A1 Yang, Eun Sung
A1 Pelc, Rebecca S.
A1 Dowd, Kimberly A.
A1 O’Hagan, Derek
A1 Ulmer, Jeffrey
A1 Mossman, Sally
A1 Sambor, Anna
A1 Lepine, Edith
A1 Mascola, John R.
A1 Pierson, Theodore C.
A1 Graham, Barney S.
A1 Yu, Dong
YR 2020
UL http://advances.sciencemag.org/content/6/32/eaba5068.abstract
AB Zika virus (ZIKV) is the cause of a pandemic associated with microcephaly in newborns and Guillain-Barre syndrome in adults. Currently, there are no available treatments or vaccines for ZIKV, and the development of a safe and effective vaccine is a high priority for many global health organizations. We describe the development of ZIKV vaccine candidates using the self-amplifying messenger RNA (SAM) platform technology delivered by cationic nanoemulsion (CNE) that allows bedside mixing and is particularly useful for rapid responses to pandemic outbreaks. Two immunizations of either of the two lead SAM (CNE) vaccine candidates elicited potent neutralizing antibody responses to ZIKV in mice and nonhuman primates. Both SAM (CNE) vaccines protected these animals from ZIKV challenge, with one candidate providing complete protection against ZIKV infection in nonhuman primates. The data provide a preclinical proof of concept that a SAM (CNE) vaccine candidate can rapidly elicit protective immunity against ZIKV.